
Anthony King
I am a freelance science journalist based in Dublin, Ireland. I cover a variety of topics in chemical and biological sciences, as well as science policy, health and innovation.
My articles have appeared in Nature, Science, Cell, Chemistry World, New Scientist, the Irish Times, New York Times, EMBO Reports, Chemistry & Industry and more.
I enjoy writing on a wide breadth of subjects, from antibiotics to petrochemicals, bumblebees to asteroid composition, palaeontology to brain development. Previously I worked for a publishing company as a science editor.
My primary degree in science is from Trinity College Dublin and I hold a Master’s degree in science communications from Dublin City University.
- Business
Two more European crackers to close
Sabic will not reopen UK plant and Dow will close another in Germany
- Business
US approves twice yearly injection to prevent HIV
Yeztugo (lenacapavir) provided near-total protection against infection in clinical trials
- News
Gene-edited crops set to arrive in England, but EU remains divided on them
Crops poised to be grown in England but renegotiation of trade agreement with EU could complicate matters
- Business
Military demand strains metal supply chains
Conflict and trade disputes have disrupted global supplies of specialist metals like hafnium, antimony and rare earths
- Feature
Hibernation awakens interest for drug discovery
With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways to treat human diseases. Anthony King reports
- Research
An overlooked bonding motif appears in many more proteins than was previously realised
Covalent nitrogen–oxygen–sulfur linkages could be a new target for potential drugs
- Business
Trade deals stave off Trump’s tariffs temporarily
Initial agreements with China and UK have paused trade war, but uncertainty reigns
- News
Materials scientist’s death at 47 from brain haemorrhage highlights long hours culture in China
Liu Yongfeng’s death isn’t the first instance of a Chinese academic with a heavy workload dying young
- Business
Ending of US weight-loss drug shortages prompts compounder complaints
Decision ends pharmacies’ permission to prepare versions of GLP-1 hormone mimics
- Business
Chevron and BP cutting thousands of jobs
Oil industry is broadly looking to cut costs, increase oil and gas production and cut renewable investments
- Research
Flea treatment-tainted pet fur lining songbird nests may be killing chicks
Multiple insecticides in blue tit and great tit nests linked to unhatched eggs, chick deaths
- Business
New type of painkiller approved in US
Sodium channel blocker prevents nerves transmitting pain signals
- Research
Mapping metabolite disturbances by drugs
High-throughput metabolomic profiling gives insight into unpredictable drug effects
- Research
Life’s ingredients discovered in samples Nasa probe returned from an asteroid
Asteroid Bennu found to contain nucleobases, amino acids and ammonia
- Feature
Low concentration chemicals spur toxicological debate
Improved analytical techniques mean tiny amounts of endocrine disrupting compounds or PFAS can be found in many places. But is it a problem? Anthony King talks to the scientists on both sides of the fence
- Business
J&J’s Intra-Cellular deal could signal more mega-mergers for 2025
£15 billion deal for neuroscience biotech aims to replace revenues from patent expiries
- Research
Mutant moulds threaten newest antifungal drugs putting immunocompromised patients at risk
Agrichemical antifungal use is leading to fungi that can evolve resistance to novel drugs faster – even those not even on the market yet
- Research
mRNA therapy might one day treat deadly pre-eclampsia in pregnant women
Therapy helped pregnant mice to regrow placental blood vessels
- Business
Opposition to lithium mines hampers green technology supply chain
Europe and US seek to escape Chinese dominance in critical minerals
- Business
Northvolt bankruptcy dents European battery industry ambitions
Swedish startup aimed to challenge Asian producers, but stumbled in scaling production